undamentalytics Newsletter
Sign in

Joint Corp (JYNT) stock

Add to watchlist

Add holding +

NASDAQ: JYNT Nasdaq Health Care Services Next results ~November 5, 2026

Joint Corp is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Joint Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling15 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds42 adding, 46 cuttingOf 16 active managers that changed their stake, 12 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Joint files

Where Joint stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $59m, down 17.8% on a year earlier, a smaller fall than the 35.8% decline a quarter earlier. Free-cash-flow margin rose to 7.2% from 4.7% a year earlier. Operating margin widened to 2.4% from -2.1%. The diluted share count is down 4.1% on a year earlier, which lifts each remaining share. It passes 2 of our 2 financial-health checks.

Our model value for Joint is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Joint Corp's trailing-twelve-month revenue fell 17.8% year on year, with a free-cash-flow margin of 7.2%.

Our discounted-cash-flow model values the business at ~$4.5 per share in the base case (~$3.8–$5.5 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth accelerating: TTM revenue growth rose to -17.8% (+18.0pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 4.5 points on a year ago.
  • Shrinking share count. Diluted shares fell 4.1% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.0bn.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 53.5% over 90 days.

Things to watch

  • Revenue shrinking. Revenue fell 17.8% over the last 12 months.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q2

Filed August 7, 2026
Earnings per share
-$0.01 against an average estimate of $0.07: missed by 114.8%
Revenue
$15m, up 14.4% on a year earlier
Share reaction
0.0% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Guidance given
system-wide sales $519m to $552m (2026); system-wide comp sales -3% to 3% (2026)
Next report
November 5, 2026; average EPS estimate $0.08

Joint's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+4.1%
  • 1 week+0.5%
  • 1 month+0.5%
  • This year-16.1%
  • 1 year-7.2%
  • 5 years-92.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$58.5M
Operating margin
2.4%
Net margin
6.5%
EPS (TTM, diluted)
$0.26

Growth

Revenue growth
−17.8%
Change in growth rate
+18.0 pts
Share count change
−4.1%

Cash

Free cash flow (TTM)
$4.2M
FCF margin
7.2%
Stock pay % of revenue
2.3%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results
  3. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Joint Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Joint Corp as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.8 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$6.1 ~$6.0–$9.6 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Joint Corp with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$5.97$2.65$4.96$8.32$16.14$26.26$65.69$13.98$9.61$10.63$8.72$7.32
Market value$60m$34m$66m$117m$234m$383m$981m$208m$144m$161m$132m$107m
+ Net debt (− = net cash)−$16m−$2m−$3m−$7m−$8m−$21m−$20m−$10m−$18m−$25m−$24m−$22m
Enterprise value$44m$31m$63m$110m$225m$362m$962m$198m$125m$136m$109m$85m
Multiples
Price / sales 4.3x1.6x2.6x3.2x4.8x6.5x12.3x2.1x1.2x3.1x2.4x1.8x
Price / earnings ———n/m70.3x29.1x129.7xn/m——45.6x28.2x
Price / free cash flow ———26.9x57.8x47.7x143.1x90.0x14.8x19.6xn/m25.3x
EV / EBITDA ———64.8x42.4x44.1x95.7x41.6x14.1x48.0x136.0x27.3x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

59 /100

Moderate moat

How hard Joint's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 16 / 20

    Cash operating profit has been a median 12.5% of total assets over 10 years.

  • Pricing power 19 / 20

    Gross margin has been a median 88.6%, moving by 2.7 percentage points (standard deviation) across 10 years.

  • Durability 0 / 20

    Operating margin has been a median 0.2%; its worst year was -48.4%.

  • Cash conversion 11 / 20

    Free cash flow was positive in 8 of 10 years, at a median 6.6% of revenue.

  • Discipline 17 / 20

    The diluted share count fell 1.1% over five years; stock-based pay has been a median 1.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (64 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $15m and EPS of $0.08 (range $0.03 to $0.12) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.13 +750% $61m +11%
Next $0.67 +412% $63m +3%

Next year's EPS estimate has moved +53.5% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −53.0% on 90 days ago. In the last 30 days, 0 analysts raised Joint Corp's forecast and 1 cut it.

Consensus EPS forecast Joint Corp, last 90 days
$0.00 $0.20 $0.40 $0.60 $0.80 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.28 Current fiscal year, 60 days ago: $0.28 Current fiscal year, 30 days ago: $0.28 Current fiscal year, 7 days ago: $0.28 Current fiscal year, Now: $0.13 $0.13 Next fiscal year, 90 days ago: $0.43 Next fiscal year, 60 days ago: $0.43 Next fiscal year, 30 days ago: $0.64 Next fiscal year, 7 days ago: $0.64 Next fiscal year, Now: $0.67 $0.67

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.28$0.43
60 days ago $0.28$0.43
30 days ago $0.28$0.64
7 days ago $0.28$0.64
Now $0.13$0.67

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.07 −$0.01 −114.8%
Mar 2026 $0.03 $0.08 +146.1%
Dec 2025 $0.04 $0.06 +50.0%
Sept 2025 $0.00 $0.13 0.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026
  • System-wide sales 2026 $519m to $552m Maintained
    “System-wide sales are expected to be between $519 million and $552 million.” source
  • System-wide comp sales 2026 -3% to 3% Maintained
    “System-wide comp sales for clinics open 13 months or more are expected to be in the range of (3)% to 3%.” source
  • Consolidated Adjusted EBITDA 2026 $12.5m to $13.5m Non-GAAP Maintained
    “Consolidated Adjusted EBITDA is expected to be in the range of $12.5 million to $13.5 million.” source
  • New franchised clinic openings 2026 22 to 26
    “New franchised clinic openings, excluding the impact of refranchised clinics, are now expected to be in the range of 22 to 26.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

4 analysts, Oct 2026
Buy125%
Hold375%
Sell00%

Monthly trend

  1. Oct 2026134
  2. Sep 2026134

Counts of recommendations published by analysts covering Joint Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.2%
of tradable shares
Days to cover
3.75
at average volume
Short interest, 1 month
−21%
to October 15, 2026
Held by institutions
70%
of shares
Held by insiders
16.2%
of shares
Employees
202
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −7.2%

$7.89 on October 31, 2025 to $7.32

ThenNowEffect
Revenue (last 12 months) $71m $59m −17.8%
P/S multiple 1.7x 1.8x +8.3%
Share count 15m 15m +4.3%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years −7.3%

$7.90 on November 3, 2023 to $7.32

ThenNowEffect
Revenue (last 12 months) $112m $59m −47.6%
Net margin 3.1% 6.5% +107.1%
P/E multiple 33.9x 28.2x −16.7%
Share count 15m 15m +2.6%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
JYNT+150%−79%−31%+11%−18%−16%
Industry peers (median)−3%−25%+8%−6%−6%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
JYNT58%25%33%58%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
JYNT−44%−80%−62%−44%−40%−35%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 94% from September 3, 2021 to October 14, 2026. Getting back needed a 1455% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$6.90 – $10.53
From 52-week high
−30.5%
vs 50-day average
−5.7%
vs 200-day average
−14.6%
Volatility (1 year)
36%
Beta vs S&P 500
0.61

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±5.6%
After a week
5 up, 7 down
typical move ±7.6%
After a month
5 up, 7 down
typical move ±7.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 0.0% +0.5% +1.1% −0.1%
May 7, 2026 −1.3% +0.5% −6.7% −6.8%
March 12, 2026 −1.3% −2.1% −4.0% +4.2%
November 6, 2025 −7.5% −1.0% −0.4% +4.2%
August 7, 2025 −3.5% +0.7% −3.2% −4.4%
July 30, 2025 −5.6% −0.5% −4.9% −8.8%
May 8, 2025 +0.5% +0.6% +1.7% +19.9%
March 13, 2025 +4.8% +0.7% +21.3% −1.1%
January 16, 2025 +9.1% +0.8% +10.0% +12.4%
November 7, 2024 −2.8% +1.2% −6.1% −3.4%
August 8, 2024 −5.1% +2.8% −2.4% −7.1%
May 2, 2024 +26.0% +2.2% +28.9% +15.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Joint Corp
$40M $60M $80M $100M $120M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $114.8M Revenue (TTM), FY23 Q4: $99.8M Revenue (TTM), FY24 Q1: $101.2M Revenue (TTM), FY24 Q2: $102.2M Revenue (TTM), FY24 Q3: $102.9M Revenue (TTM), FY24 Q4: $104.9M Revenue (TTM), FY25 Q1: $88.3M Revenue (TTM), FY25 Q2: $71.3M Revenue (TTM), FY25 Q3: $54.4M Revenue (TTM), FY25 Q4: $54.9M Revenue (TTM), FY26 Q1: $56.6M Revenue (TTM), FY26 Q2: $58.5M $58.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $114.8M
FY23 Q4 $99.8M
FY24 Q1 $101.2M
FY24 Q2 $102.2M
FY24 Q3 $102.9M
FY24 Q4 $104.9M
FY25 Q1 $88.3M
FY25 Q2 $71.3M
FY25 Q3 $54.4M
FY25 Q4 $54.9M
FY26 Q1 $56.6M
FY26 Q2 $58.5M
Revenue growth, TTM YoY Joint Corp
-60% -40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 21.0% Revenue growth, TTM YoY, FY23 Q4: -1.4% Revenue growth, TTM YoY, FY24 Q1: -5.7% Revenue growth, TTM YoY, FY24 Q2: -8.6% Revenue growth, TTM YoY, FY24 Q3: -10.3% Revenue growth, TTM YoY, FY24 Q4: 5.1% Revenue growth, TTM YoY, FY25 Q1: -12.8% Revenue growth, TTM YoY, FY25 Q2: -30.2% Revenue growth, TTM YoY, FY25 Q3: -47.1% Revenue growth, TTM YoY, FY25 Q4: -47.7% Revenue growth, TTM YoY, FY26 Q1: -35.8% Revenue growth, TTM YoY, FY26 Q2: -17.8% -17.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 21.0%
FY23 Q4 -1.4%
FY24 Q1 -5.7%
FY24 Q2 -8.6%
FY24 Q3 -10.3%
FY24 Q4 5.1%
FY25 Q1 -12.8%
FY25 Q2 -30.2%
FY25 Q3 -47.1%
FY25 Q4 -47.7%
FY26 Q1 -35.8%
FY26 Q2 -17.8%
Operating margin (TTM) Joint Corp
-4% -2% 0% 2% 4% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -1.7% Operating margin (TTM), FY23 Q4: 0.3% Operating margin (TTM), FY24 Q1: 0.1% Operating margin (TTM), FY24 Q2: -0.8% Operating margin (TTM), FY24 Q3: -1.2% Operating margin (TTM), FY24 Q4: -1.4% Operating margin (TTM), FY25 Q1: -1.9% Operating margin (TTM), FY25 Q2: -2.1% Operating margin (TTM), FY25 Q3: -1.6% Operating margin (TTM), FY25 Q4: -1.7% Operating margin (TTM), FY26 Q1: 1.1% Operating margin (TTM), FY26 Q2: 2.4% 2.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -1.7%
FY23 Q4 0.3%
FY24 Q1 0.1%
FY24 Q2 -0.8%
FY24 Q3 -1.2%
FY24 Q4 -1.4%
FY25 Q1 -1.9%
FY25 Q2 -2.1%
FY25 Q3 -1.6%
FY25 Q4 -1.7%
FY26 Q1 1.1%
FY26 Q2 2.4%
FCF margin (TTM) Joint Corp
0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 9.6% FCF margin (TTM), FY23 Q4: 9.7% FCF margin (TTM), FY24 Q1: 7.2% FCF margin (TTM), FY24 Q2: 6.0% FCF margin (TTM), FY24 Q3: 6.4% FCF margin (TTM), FY24 Q4: 7.8% FCF margin (TTM), FY25 Q1: 2.0% FCF margin (TTM), FY25 Q2: 4.7% FCF margin (TTM), FY25 Q3: 3.0% FCF margin (TTM), FY25 Q4: 0.6% FCF margin (TTM), FY26 Q1: 4.7% FCF margin (TTM), FY26 Q2: 7.2% 7.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 9.6%
FY23 Q4 9.7%
FY24 Q1 7.2%
FY24 Q2 6.0%
FY24 Q3 6.4%
FY24 Q4 7.8%
FY25 Q1 2.0%
FY25 Q2 4.7%
FY25 Q3 3.0%
FY25 Q4 0.6%
FY26 Q1 4.7%
FY26 Q2 7.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 6 7 14 21 25 37 48 59 80 101 118 52 55 59
Gross profit 4 5 11 18 22 32 43 52 72 90 107 41 44 48
EBITDA 1 −1 −8 −12 −1 2 5 8 10 5 9 3 1 3
Operating income 0 −2 −9 −15 −3 0 3 5 6 −2 0 −2 −1 1
Net income 0 −3 −9 −15 −3 0 3 13 8 1 −10 −6 3 4
Diluted EPS $0.02 −$0.56 −$0.88 −$1.20 −$0.26 $0.01 $0.23 $0.90 $0.51 −$0.38 −$0.65 −$0.38 $0.19 $0.26
Growth (year on year)
Revenue — +19.4% +94.4% +48.3% +21.4% +47.1% +32.2% +21.1% +36.3% +26.5% +16.2% −55.7% +5.2% −17.8%
EBITDA — −377.5% — — — — +212.8% +54.8% +22.1% −52.7% +87.1% −68.2% −71.8% —
Operating income — −469.9% — — — — — +60.8% +11.5% −130.8% — — — —
Net income — <−999% — — — — — +296.2% −42.5% −91.7% — — — —
Diluted EPS — <−999% — — — — — +291.3% −43.3% −174.5% — — — —
Margins
Gross margin 66.3% 67.0% 79.6% 85.7% 87.1% 88.2% 88.5% 88.9% 90.4% 88.6% 91.1% 77.9% 79.6% 81.8%
EBITDA margin 8.6% −19.9% −58.2% −60.6% −5.3% 4.6% 11.0% 14.0% 12.6% 4.7% 7.6% 5.4% 1.5% 5.3%
Operating margin 7.4% −22.9% −67.3% −73.1% −13.4% 0.4% 7.0% 9.4% 7.7% −1.9% 0.3% −3.6% −1.7% 2.4%
Net margin 2.6% −42.6% −63.6% −73.9% −13.8% 0.4% 6.9% 22.4% 9.5% 0.6% −8.3% −11.1% 5.3% 6.5%
Free-cash-flow margin 3.0% −15.4% −78.5% −60.5% −2.1% 11.8% 8.3% 13.7% 8.6% 2.3% 8.2% 15.8% 0.6% 7.2%
Cash flow
Cash from operations 0 −0 −7 −11 −0 5 8 11 14 8 15 9 2 5
Capital spending 0 1 4 2 0 1 3 3 7 6 5 1 2 1
Free cash flow 0 −1 −11 −12 −1 4 4 8 7 2 10 8 0 4
Stock-based pay — 0 1 1 1 1 1 1 1 1 2 2 1 1
Free cash flow after stock pay — −1 −12 −14 −1 4 3 7 6 1 8 7 −1 3
Balance sheet
Cash 4 21 17 3 4 9 8 21 20 10 18 25 24 22
Total debt 0 0 1 1 1 2 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −4 −21 −16 −2 −3 −7 −8 −21 −20 −10 −18 −25 −24 −22
Diluted shares 7m 5m 10m 13m 13m 14m 14m 15m 15m 15m 15m 15m 15m 15m
Returned to shareholders
Buybacks 0 — — 0 0 0 0 0 1 0 0 0 11 13
Total returned 0 — — 0 0 0 0 0 1 0 0 0 11 13

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $52m
Short-term assets $44mLonger-term assets $8m
What it owes, and who funded it · $52m
Short-term liabilities $24mLonger-term liabilities $12mShareholders' equity $16m
  • Short-term assets cover short-term liabilities $44m of assets due within a year against $24m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $44m short-term assets against $12m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Joint Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$13.1M
Returned to shareholders
311%
of free cash flow
Buybacks, last 3 fiscal years
$11.3M
Diluted share count
−4.1%
year over year
Total shareholder yield
12.6%
dividends 0.0% + buybacks 12.6% of market value
Sales & admin spending
79.0%
of revenue
Days sales outstanding
15 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated JYNT HAO CCEL AMS RDGT NRC Median
Revenue, last 12 months $59m $55m $31m $30m $132m $140m $1.1bn
Revenue growth, last 12 months −17.8% 67.1% −2.0% 4.0% 10.2% −0.2% 7.2%
Revenue growth, 3-year average −19.4% — −0.1% 14.3% — −1.9% 11.2%
Revenue growth, latest quarter 14.4% — −0.0% 19.2% — 4.0% 8.6%
Gross margin 81.8% 1.1% 78.5% 17.1% 3.6% — 27.9%
Operating margin 2.4% −17.6% 0.6% −11.8% −1.4% 10.5% 2.4%
Operating margin, 3-year average −0.2% — −8.4% −8.5% — 19.1% 2.0%
Net margin 6.5% −17.4% −6.2% −5.8% −0.9% 4.0% 1.2%
Cash from operations / revenue 9.2% −4.7% 15.8% 17.6% −1.1% 21.1% 6.3%
Free-cash-flow margin 7.2% −5.2% 14.9% 11.6% −1.1% 15.5% 5.2%
Free-cash-flow margin, 3-year average 6.0% — 14.7% −14.8% — 12.5% 3.7%
Stock pay / revenue 2.3% 0.2% 1.1% 1.3% 8.6% 8.4% 1.1%
Change in share count −4.1% >999% −1.4% 0.4% 96.6% −5.2% 0.3%

Median of all 42 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Royalty $33.2M 60.5% ▲ 3.3%
Advertising $10.5M 19.0% ▲ 13.8%
Technology services $6M 11.0% ▲ 6.2%
Franchise $3.4M 6.1% ▲ 12.5%
Other $1.8M 3.3% ▼ 14.9%

From Joint Corp's 10-K filed March 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$83.7M
Institutions reporting
82
Shares held vs prior quarter
▼ 7.2%
Positions opened / closed
19 / 18

Top buyers and sellers, Q2 2026: 42 institutions bought and 46 sold ; the biggest buyer was Jane Street Group, LLC (+174K shares) and the biggest seller Blackrock, Inc (−466K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Bandera Partners LLC $34.6M 3.9M 41.3% 0.0%
Skylands Capital, LLC $7.9M 896K 9.4% ▲ 0.3%
Jcp Investment Management, LLC $5.2M 594K 6.2% 0.0%
Vanguard Capital Management LLC $4.9M 557K 5.8% ▼ 6.5%
First Foundation Advisors $2.9M 335K 3.5% ▼ 0.9%
Blackrock, Inc. $2.5M 289K 3.0% ▼ 61.7%
Russell Investments Group, Ltd. $2.5M 285K 3.0% ▼ 11.4%
Jane Street Group, LLC $2.1M 236K 2.5% ▲ 281.5%
Vanguard Portfolio Management LLC $2M 225K 2.4% ▼ 19.1%
Renaissance Technologies LLC $1.9M 219K 2.3% ▼ 4.0%
Geode Capital Management, LLC $1.4M 154K 1.6% ▼ 46.5%
Dimensional Fund Advisors LP $1.3M 150K 1.6% ▼ 2.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Joint Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $2M 15 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $2M net buying
Insider Date Trade Shares Price Value
Jobson Charles E 10% owner May 13, 2026 Buy 20,375 $8.57 $174,614
Jobson Charles E 10% owner May 12, 2026 Buy 127,676 $8.57 $1.1M
Jobson Charles E 10% owner April 21, 2026 Buy 509 $8.58 $4,367
Jobson Charles E 10% owner February 12, 2026 Buy 15,397 $8.50 $130,874
Jobson Charles E 10% owner February 11, 2026 Buy 448 $8.70 $3,898
Jobson Charles E 10% owner January 26, 2026 Buy 725 $10.00 $7,250
Jobson Charles E 10% owner January 23, 2026 Buy 16,753 $10.00 $167,530
Jobson Charles E 10% owner January 6, 2026 Buy 5,240 $8.89 $46,584
Jobson Charles E 10% owner January 2, 2026 Buy 1,393 $8.70 $12,119
Jobson Charles E 10% owner December 31, 2025 Buy 11 $8.70 $96
Jobson Charles E 10% owner December 5, 2025 Buy 10,000 $8.41 $84,100
Jobson Charles E 10% owner December 1, 2025 Buy 13,000 $8.41 $109,330

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 6, 2026
  • May 7, 2026
  • March 12, 2026
  • November 6, 2025
  • August 7, 2025
  • July 30, 2025

Recent SEC filings

Data status

When each part of this page on Joint Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Joint Corp in brief

What does Joint Corp do?
Joint Corp is a US-listed company in the health care services industry. Its financial year ends in December.
What is Joint Corp's stock ticker?
Joint Corp trades under the ticker JYNT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Joint Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Joint Corp reported revenue of $58.5M, 17.8% lower than a year earlier, according to its SEC filings.
What is Joint Corp's free cash flow?
Joint Corp's free-cash-flow margin is 7.2% of revenue over the trailing twelve months.
Who are Joint Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Bandera Partners LLC, Skylands Capital, LLC and Jcp Investment Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Joint Corp buying back stock, and does it pay a dividend?
Joint Corp spent $13.1M on share repurchases over the trailing twelve months, and its diluted share count fell 4.1% over the year.
What is Joint Corp's market cap?
On November 2, 2026, Joint Corp's market capitalisation was about $107M, with a price-to-earnings ratio of 28.2 and net debt of -$22.2M. Market figures come from third-party market data and may be delayed.
Who are Joint Corp's competitors?
In our Health Care Services peer group, the companies closest to Joint Corp are Haoxi Health Technology Ltd, Cryo Cell International Inc, American Shared Hospital Services, Ridgetech Inc. and NRC Health. The side-by-side comparison below sets their revenue, margins and growth against Joint Corp's.
Are insiders buying or selling Joint Corp stock?
Over the last 12 months, Joint Corp's directors and officers reported 15 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Joint Corp's next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Joint Corp announces its own schedule.